SPRB
Price
$0.38
Change
+$0.01 (+2.70%)
Updated
Jan 22, 04:59 PM (EDT)
Capitalization
15.59M
49 days until earnings call
URGN
Price
$10.07
Change
-$0.12 (-1.18%)
Updated
Jan 22, 04:59 PM (EDT)
Capitalization
424.1M
50 days until earnings call
Ad is loading...

SPRB vs URGN

Header iconSPRB vs URGN Comparison
Open Charts SPRB vs URGNBanner chart's image
Spruce Biosciences
Price$0.38
Change+$0.01 (+2.70%)
Volume$39.89K
Capitalization15.59M
UroGen Pharma
Price$10.07
Change-$0.12 (-1.18%)
Volume$8.88K
Capitalization424.1M
SPRB vs URGN Comparison Chart
Loading...
SPRB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
URGN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
SPRB vs. URGN commentary
Jan 23, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is SPRB is a Hold and URGN is a Hold.

Ad is loading...
COMPARISON
Comparison
Jan 23, 2025
Stock price -- (SPRB: $0.37 vs. URGN: $10.19)
Brand notoriety: SPRB and URGN are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: SPRB: 11% vs. URGN: 59%
Market capitalization -- SPRB: $15.59M vs. URGN: $424.1M
SPRB [@Biotechnology] is valued at $15.59M. URGN’s [@Biotechnology] market capitalization is $424.1M. The market cap for tickers in the [@Biotechnology] industry ranges from $355.19B to $0. The average market capitalization across the [@Biotechnology] industry is $2.34B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

SPRB’s FA Score shows that 1 FA rating(s) are green whileURGN’s FA Score has 0 green FA rating(s).

  • SPRB’s FA Score: 1 green, 4 red.
  • URGN’s FA Score: 0 green, 5 red.
According to our system of comparison, SPRB is a better buy in the long-term than URGN.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

SPRB’s TA Score shows that 4 TA indicator(s) are bullish while URGN’s TA Score has 5 bullish TA indicator(s).

  • SPRB’s TA Score: 4 bullish, 2 bearish.
  • URGN’s TA Score: 5 bullish, 2 bearish.
According to our system of comparison, URGN is a better buy in the short-term than SPRB.

Price Growth

SPRB (@Biotechnology) experienced а +0.65% price change this week, while URGN (@Biotechnology) price change was +2.62% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +1.78%. For the same industry, the average monthly price growth was +2.45%, and the average quarterly price growth was -2.46%.

Reported Earning Dates

SPRB is expected to report earnings on May 07, 2025.

URGN is expected to report earnings on May 08, 2025.

Industries' Descriptions

@Biotechnology (+1.78% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
URGN($424M) has a higher market cap than SPRB($15.6M). URGN YTD gains are higher at: -4.319 vs. SPRB (-11.000). SPRB has higher annual earnings (EBITDA): -39.02M vs. URGN (-97.82M). URGN has more cash in the bank: 250M vs. SPRB (60.1M). SPRB has less debt than URGN: SPRB (3.23M) vs URGN (122M). URGN has higher revenues than SPRB: URGN (89.4M) vs SPRB (7.1M).
SPRBURGNSPRB / URGN
Capitalization15.6M424M4%
EBITDA-39.02M-97.82M40%
Gain YTD-11.000-4.319255%
P/E RatioN/AN/A-
Revenue7.1M89.4M8%
Total Cash60.1M250M24%
Total Debt3.23M122M3%
FUNDAMENTALS RATINGS
URGN: Fundamental Ratings
URGN
OUTLOOK RATING
1..100
59
VALUATION
overvalued / fair valued / undervalued
1..100
76
Overvalued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
100
PRICE GROWTH RATING
1..100
85
P/E GROWTH RATING
1..100
100
SEASONALITY SCORE
1..100
50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
SPRBURGN
RSI
ODDS (%)
N/A
Bullish Trend 15 days ago
77%
Stochastic
ODDS (%)
Bullish Trend 15 days ago
85%
Bullish Trend 15 days ago
84%
Momentum
ODDS (%)
Bullish Trend 15 days ago
82%
Bullish Trend 15 days ago
82%
MACD
ODDS (%)
Bullish Trend 15 days ago
89%
Bullish Trend 15 days ago
90%
TrendWeek
ODDS (%)
Bearish Trend 15 days ago
87%
Bullish Trend 15 days ago
82%
TrendMonth
ODDS (%)
Bearish Trend 15 days ago
88%
Bearish Trend 15 days ago
88%
Advances
ODDS (%)
Bullish Trend 27 days ago
78%
Bullish Trend 20 days ago
79%
Declines
ODDS (%)
Bearish Trend 15 days ago
87%
Bearish Trend 24 days ago
87%
BollingerBands
ODDS (%)
N/A
N/A
Aroon
ODDS (%)
Bearish Trend 15 days ago
85%
Bearish Trend 15 days ago
88%
View a ticker or compare two or three
Ad is loading...
SPRB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
URGN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
TYL584.5515.22
+2.67%
Tyler Technologies
IVDA4.320.10
+2.37%
Iveda Solutions Inc
NWL10.240.12
+1.19%
Newell Brands
EVRI13.600.03
+0.22%
Everi Holdings
PAYS2.89-0.14
-4.77%
Paysign

SPRB and

Correlation & Price change

A.I.dvisor indicates that over the last year, SPRB has been loosely correlated with MLEC. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if SPRB jumps, then MLEC could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SPRB
1D Price
Change %
SPRB100%
+2.47%
MLEC - SPRB
51%
Loosely correlated
-7.33%
IMRX - SPRB
51%
Loosely correlated
+4.95%
FATE - SPRB
45%
Loosely correlated
+3.94%
SCPX - SPRB
43%
Loosely correlated
-18.38%
GNFT - SPRB
39%
Loosely correlated
+5.48%
More

URGN and

Correlation & Price change

A.I.dvisor indicates that over the last year, URGN has been loosely correlated with CYYNF. These tickers have moved in lockstep 38% of the time. This A.I.-generated data suggests there is some statistical probability that if URGN jumps, then CYYNF could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To URGN
1D Price
Change %
URGN100%
-0.78%
CYYNF - URGN
38%
Loosely correlated
N/A
SPRB - URGN
33%
Loosely correlated
+2.47%
TRDA - URGN
30%
Poorly correlated
+2.92%
PLRX - URGN
30%
Poorly correlated
-1.25%
MREO - URGN
29%
Poorly correlated
+4.55%
More